2006
A step in the right direction
DeVita V. A step in the right direction. Nature Reviews Clinical Oncology 2006, 3: 641-641. PMID: 17139311, DOI: 10.1038/ncponc0669.Peer-Reviewed Original ResearchLet's return to the “belly bath”
DeVita V. Let's return to the “belly bath”. Nature Reviews Clinical Oncology 2006, 3: 405-405. PMID: 16894365, DOI: 10.1038/ncponc0568.Peer-Reviewed Original Research
1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaDialysisFemaleHumansInjections, IntraperitonealMelanomaMethotrexateOvarian NeoplasmsConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchMeSH KeywordsColonic NeoplasmsDrug Administration ScheduleDrug EvaluationFemaleFluorouracilHumansInjections, IntraperitonealOvarian NeoplasmsConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levels
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvivalHexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologicHigh volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer
Jones R, Myers C, Guarino A, Dedrick R, Hubbard S, DeVita V. High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer. Cancer Chemotherapy And Pharmacology 1978, 1: 161-166. PMID: 373916, DOI: 10.1007/bf00253116.Peer-Reviewed Original ResearchConceptsOvarian cancerIntraperitoneal chemotherapyPhase I clinical trialAdvanced stage diseaseIntraperitoneal fluid volumeIntraperitoneal methotrexateComplete remissionTreatment modalitiesPharmacologic principlesClinical trialsPeritoneal cavityTherapeutic effectivenessChemotherapyPharmacokinetic modelingDialysis fluidToxicologic studiesCancerFluid volumeDrug distributionRational chemotherapyFurther investigationRemissionPatientsMethotrexatePharmacokineticsPharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1976
Perspectives on research in gynecologic oncology. Treatment protocols
Devita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAlkylating AgentsAntineoplastic AgentsCarcinoma, Squamous CellClinical Trials as TopicDrug EvaluationDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProgestinsUterine Cervical NeoplasmsUterine NeoplasmsConceptsClinical trialsOvarian cancerAdvanced uterine cancerPostoperative adjuvant chemotherapyStage II diseaseMetastatic cervical cancerEffective adjuvant treatmentEffect of radiotherapyUse of adriamycinUse of hydroxyureaCombination of drugsL-phenylalanine mustardPathways of spreadMore effective drugsAdjuvant chemotherapyInoperable diseaseResectable tumorsAdjuvant treatmentAdvanced diseasePostoperative radiotherapySystemic chemotherapyGynecologic malignanciesSystemic treatmentTreatment failureUterine cervix
1975
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young R, Chabner B, Hubbard S, Canellos G, DeVita V. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. National Cancer Institute Monograph 1975, 42: 145-8. PMID: 825777.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaOvarian carcinomaHigher overall response rateOral alkylating agentTrials of chemotherapyOverall response ratePAM therapyNational Cancer InstituteIntravenous cyclophosphamideSystemic chemotherapyRemission rateCombination therapyProspective trialsHigh-doseTherapeutic efficacyConventional treatmentResponse rateCancer InstituteChemotherapyAlkylating agentsCarcinomaTherapyTrialsCyclophosphamideMelphalanIntroduction. Ovarian cancer, an enigma wrapped in a puzzle.
DeVita V. Introduction. Ovarian cancer, an enigma wrapped in a puzzle. Seminars In Oncology 1975, 2: 189-90. PMID: 1234799.Peer-Reviewed Original ResearchPeritoneoscopy: a valuable staging tool in ovarian carcinoma.
Rosenoff S, Young R, Anderson T, Bagley C, Chabner B, Schein P, Hubbard S, DeVita V. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Annals Of Internal Medicine 1975, 83: 37-41. PMID: 125057, DOI: 10.7326/0003-4819-83-1-37.Peer-Reviewed Original ResearchConceptsOvarian carcinomaApparent clinical remissionValuable staging toolAdvanced diseaseClinical remissionExploratory laparotomyConsecutive patientsDiaphragmatic involvementPretreatment evaluationAbdominal radiotherapyTherapeutic failureLaboratory examinationsStaging toolPatientsCarcinomaLiver areaLaparotomyPeritoneoscopySecond lookPercentRemissionRadiotherapyRoentgenologicTherapyPelvisSingle agent versus combination chemotherapy
DeVita V. Single agent versus combination chemotherapy. CA A Cancer Journal For Clinicians 1975, 25: 152-158. PMID: 165865, DOI: 10.3322/canjclin.25.3.152.Peer-Reviewed Original ResearchAmerican Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations
Banks P, Arseneau J, Gralnick H, Canellos G, DeVita V, Berard C. American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations. The American Journal Of Medicine 1975, 58: 322-329. PMID: 163581, DOI: 10.1016/0002-9343(75)90598-7.Peer-Reviewed Original ResearchMeSH KeywordsAbdomenAdolescentAdultAutopsyBiopsyBone MarrowBurkitt LymphomaChildChild, PreschoolCytoplasmFemaleHumansInclusion BodiesIntestinal NeoplasmsIntestine, SmallLiverLymphatic MetastasisMacrophagesMaleMandibular NeoplasmsMaxillary NeoplasmsNorth AmericaOvarian NeoplasmsSouth AmericaUnited StatesConceptsMonths of therapyBone marrow involvementOlder median ageCentral nervous systemInitial therapyClinicopathologic studyMarrow involvementBurkitt's typeMedian ageMultiorgan involvementMalignant lymphomaShorter survivalMassive infiltrationAmerican patientsPelvic sitesPathologic correlationDiffuse necrosisHistologic appearanceTherapeutic implicationsOrgan sitesBone marrowNervous systemEndemic regionsTumor cellsLymphomaCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
Devita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAlkylating AgentsAntineoplastic AgentsBinding, CompetitiveBreast NeoplasmsBurkitt LymphomaChoriocarcinomaCyclophosphamideDrug ResistanceDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLeukemia, LymphoidNeoplasm MetastasisNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPregnancy
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapyThe design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCystadenocarcinomaCystadenomaEndometriosisFemaleHumansOvarian NeoplasmsPrognosisResearch DesignConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomen
1973
Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary report
Bagley C, Young R, Schein P, Chabner B, Devita V. Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary report. American Journal Of Obstetrics And Gynecology 1973, 116: 397-400. PMID: 4267636, DOI: 10.1016/s0002-9378(15)31299-0.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyDiaphragmFemaleHumansLaparoscopyLaparotomyLiver NeoplasmsNeoplasm MetastasisOvarian NeoplasmsConceptsDiaphragmatic metastasisOvarian carcinomaOvarian carcinoma metastaticStage IA diseaseUpper abdominal metastasisIA diseaseAbdominal metastasesCarcinoma metastaticHigh incidenceMetastasisPatientsCarcinomaPreliminary reportRadiotherapyOnly siteDirect visualizationDiaphragmLaparotomyMetastaticPeritoneoscopyIncidenceDiseasePhysiciansLiverWeeks
1972
Treatment of Ovarian Carcinoma: Possibilities for Progress
Bagley C, Young R, Canellos G, DeVita V. Treatment of Ovarian Carcinoma: Possibilities for Progress. New England Journal Of Medicine 1972, 287: 856-862. PMID: 4561148, DOI: 10.1056/nejm197210262871705.Peer-Reviewed Original Research